ICIs showed unsatisfactory efficacy in patients with mucosal melanoma both as anti-PD-1 monotherapy and in combination with ipilimumab (3–6), which could be attributed to the low TMB and PD-L1 expression (7, 25, 26). This evidence concerns the gene CD274 and mucosal melanoma.